Donor lymphocyte infusion administrations after allogeneic stem cell transplantations in pediatrics: A single center experience
[ X ]
Tarih
2019
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Nature Publishing Group
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use.
Açıklama
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT) -- MAR 24-27, 2019 -- Frankfurt, GERMANY
Anahtar Kelimeler
Donors, Allogeneic Stem Cell, Pediatrics
Kaynak
Bone Marrow Transplantation
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
54
